North America Opioids Market To Reach $15.3 Billion By 2030

North America Opioids Market Growth & Trends

The North America opioids market is expected to reach USD 15.3 billion by 2030, growing at an estimated CAGR of 0.8% from 2023 to 2030, according to a new study by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, conducive for research and development as well as commercialization efforts directed toward the development of novel abuse-deterrent opioids, to flourish and drive the industry growth during the forecast period. Furthermore, the key players are deploying large funds in the development of abuse-deterrent technology wherein drugs are designed to be tamper resistant. This is achieved through alterations involving, among others, the use of physical or chemical barriers to resist convenient extraction of the opioids, the addition of an aversive agent to the formulation that would yield an unpleasant effect upon its extraction, and the formulation of opioid prodrugs that are dependent on enzymatic activity in order to be rendered to their active forms. These tamper-resistant opioid drug forms are anticipated to mitigate the incidence of their misuse.

Opioids are the mainstay of chronic pain management that is used to alleviate varied pain conditions. Opiates including codeine and morphine are frequently employed as cough suppression medication. Codeine is considered as a gold standard for cough suppression since it has minimal side effects. Moreover, these narcoticsare used in the treatment of irritable bowel syndrome-induced diarrhea since they act on gastrointestinal receptors. In addition, peripherally acting loperamide is commonly used to suppress diarrhea. Thus, theprofitable growth of the Opioid Market lies in its breadth of applications in the management of diverse conditions including cough, diarrhea, and pain.

 Request a free sample copy or view report summary: North America Opioids Market Report

North America Opioids Market Report Highlights

• The extended-release opioids segment accounted for the largest share over 53.8% in 2022. The dominance of the segment is attributed to the high usage of these drugs for chronic pain management and the development of innovative dosage forms, such as transdermal patches.

• Market share of the immediate-release dosage forms including morphine and codeine, is expected to decline owing to the frequent product recalls and severe side effects associated with their use.

• In terms of applications, The pain relief segment dominated the market with the largest revenue share in 2022. The extensive amount of pain caused during chemotherapy and radiotherapy are the primary factors resulting in the increasing incorporation of these drugs in the cancer segment.

• The post-operative pain management segment is expected to be the fastest growing application in the pain relief category. As a result of their high applicability in post- surgical pain management, the rise in number of surgical procedures is expected to fuel the sector penetration of opioids in the near future.

• The U.S. dominated the market with the highest revenue share of 95.6% in 2022. One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.

• In addition, the increasing adoption of opioids for pain management related to trauma and injury cases, in severe and chronic disabling diseases, and in cases of post-surgical pain, is driving the growth of the market in the North America region

• The Canada is expected to grow at the fastest growth rate of 1.2% over the forecast period owing to the demand arising from the increasing prevalence of various pain-related conditions, such as cancer-related pain, musculoskeletal disorders, and post-operative pain. In addition, the growing aging population in Canada has further contributed to the demand for opioids.

North America Opioids Market Segmentation

Grand View Research has segmented the North America opioids market on the basis of product, application, and region:

North America Opioids Product Outlook (Revenue, USD Million, 2018 - 2030)

• Immediate Release/Short-acting Opioids

  • Codeine

  • Oxycodone

  • Hydrocodone

  • Fentanyl

  • Morphine

  • Hydroxymorphone

  • Oxymorphone

  • Propoxyphene

  • Others

• Extended Release/Long-acting Opioids

  • Oxycodone

  • Hydrocodone

  • Methadone

  • Fentanyl

  • Morphine

  • Oxymorphone

  • Tapentadol

  • Buprenorphine

  • Hydromorphone

  • Others

North America Opioids Application Outlook (Revenue, USD Million, 2018 - 2030)

• Pain Relief

  • Cancer pain

  • Post-Operative Care

  • Lower Back Pain

  • Orthopedic

  • Neuropathic

  • Fibromyalgia

• Anesthesia

• Cough Suppression

• Diarrhea Suppression

• De-Addiction

North America Opioids Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

List Of Key Players in the North America Opioids Market

• Purdue Pharma L.P.

• Janssen Global Services, LLC

• Hikma Pharmaceuticals PLC

• Pfizer Inc.

• AbbVie Inc.

• Sanofi

• Sun Pharmaceutical Industries Ltd.

• Mallinckrodt Pharmaceuticals

• Endo Pharmaceuticals

• Teva Pharmaceutical Industries